Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

17p cytogenetic changes in TP53-mutated AML

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSharon SanthoshASAdit SinghalJKJonathan E. Kolitz

Discussion

Loading...

Member takes

Overview

Analysis finds 17p cytogenetic changes and TP53 mutations correlate with poor clinical outcomes in AML.

Key Points

  • To investigate the impact of 17p cytogenetic changes on clinical outcomes in patients with TP53-mutated AML.
  • Retrospective review of AML cases diagnosed from 2019 to 2024
  • Utilized next-generation sequencing, karyotyping, and fluorescence in-situ hybridization for analysis
  • Examined survival outcomes using Kaplan-Meier analysis and log-rank testing.
  • 92 evaluable cases of TP53-mutated AML included in the analysis
  • 85.9% had at least one TP53 point mutation
  • 70.7% exhibited chromosomal abnormalities involving 17p
  • No specific 17p abnormality led to improved overall survival

Cite This Study

Santhosh et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da39https://doi.org/10.1182/blood-2025-3506
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 117p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease2025
  2. 2Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report2025 · 2 citations
  3. 3Abstract 5302: Defining the landscape of TP53 mutations in acute myeloid leukemia2026
  4. 4Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation2026
  5. 5Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.2024